The price-to-earnings ratio for Johnson & Johnson (NYSE: JNJ) is above average at 17.26x, Company’s 36-month beta value is 0.41.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 13 as “hold,” and 0 as “sell.”
The public float for JNJ is 2.40B, and currently, short sellers hold a 0.80% ratio of that floaft. The average trading volume of JNJ on June 16, 2025 was 8.97M shares.
JNJ) stock’s latest price update
Johnson & Johnson (NYSE: JNJ) has seen a decline in its stock price by -1.19 in relation to its previous close of 157.10. zacks.com reported 2025-06-16 that JNJ’s Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
JNJ’s Market Performance
JNJ’s stock has fallen by -0.00% in the past week, with a monthly rise of 3.76% and a quarterly drop of -4.67%. The volatility ratio for the week is 0.76% while the volatility levels for the last 30 days are 0.63% for Johnson & Johnson The simple moving average for the last 20 days is 0.57% for JNJ stock, with a simple moving average of -0.68% for the last 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with Leerink Partners repeating the rating for JNJ by listing it as a “Market Perform.” The predicted price for JNJ in the upcoming period, according to Leerink Partners is $153 based on the research report published on May 13, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $166. The rating they have provided for JNJ stocks is “Neutral” according to the report published on December 10th, 2024.
Wolfe Research gave a rating of “Outperform” to JNJ, setting the target price at $190 in the report published on November 15th of the previous year.
JNJ Trading at 0.85% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.68% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JNJ starting from Decker Robert J, who sale 6,999 shares at the price of $165.88 back on Feb 25 ’25. After this action, Decker Robert J now owns 21,001 shares of Johnson & Johnson, valued at $1,160,994 using the latest closing price.
Decker Robert J, the Officer of Johnson & Johnson, proposed sale 6,999 shares at $165.88 during a trade that took place back on Feb 25 ’25, which means that Decker Robert J is holding shares at $1,161,010 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.68 for the gross margin
The net margin for Johnson & Johnson stands at 0.24. The total capital return value is set at 0.16. Equity return is now at value 29.45, with 11.93 for asset returns.
Based on Johnson & Johnson (JNJ), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at 0.47. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is 27.46.
Currently, EBITDA for the company is 24.78 billion with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 4.33. The receivables turnover for the company is 5.58for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In a nutshell, Johnson & Johnson (JNJ) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
